Martin W. Edwards

Martin Edwards is a Senior Partner in Novo Ventures, Novo A/S.

Dr. Edwards joined Novo A/S in 2003 working out of London. He is a member of the board of directors of Funxional Therapeutics Ltd, Logical Therapeutics, Inc., Serentis Ltd, Tarsa Therapeutics Ltd, and Vantia Therapeutics Ltd, and chairman of the board of directors of Symphogen A/S, and is an adjunct professor at the Scandinavian International Management Institute.

From 1998-2003, Martin was CEO of ReNeuron Holdings, taking that company public in 2000 and raising a total of £25m in equity and debt financing. From 1994-1998, he was Corporate V.P and Head of Drug Development for Novo Nordisk A/S where he was responsible for all aspects of pre-clinical and clinical drug development.

Previously, Martin worked for six years in the USA first as V.P Pharmacology and Medical Affairs of ZymoGenetics, Inc. in Seattle, and then as Senior V.P for Medical Affairs at Novo Nordisk in Princeton N.J.